Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1997 May;52(5):458-64.
doi: 10.1136/thx.52.5.458.

Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects

Affiliations
Clinical Trial

Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects

J A Bennett et al. Thorax. 1997 May.

Abstract

Background: The main adverse effects of beta 1 agonists relate to their systemic activity. The time course and dose response relations of the systemic effects of salmeterol compared with salbutamol were investigated.

Methods: A double blind, randomised, crossover study was carried out in 14 healthy subjects who attended on seven days. Heart rate, QTc interval, blood pressure, plasma potassium and glucose concentrations were measured for four hours following inhaled placebo, salmeterol 100, 200 and 400 micrograms and salbutamol 600, 1200 and 2400 micrograms given by metered dose inhaler. Maximum changes from baseline and maximum absolute values following each dose of treatment were used to construct log dose response curves and calculate relative dose potency.

Results: Both salmeterol and salbutamol caused dose dependent changes in heart rate, QTc interval, and plasma potassium and glucose concentrations. The onset of cardiac effects was rapid following both drugs, whereas changes in glucose and potassium concentrations occurred more gradually with salmeterol. The increase in heart rate and fall in potassium level were sustained over the four hours whereas glucose levels gradually returned towards baseline. The relative dose potency of salmeterol compared with salbutamol for changes from baseline was 7.1 (95% CI 3.9 to 14.4) for the QTc interval and 8.2 (95% CI 5.7 to 12.6) for plasma potassium concentration. Salmeterol caused steeper dose response curves for heart rate and plasma glucose concentration than salbutamol so relative dose potency values could not be calculated.

Conclusions: These findings support previous data that salmeterol 100 micrograms is broadly equivalent to salbutamol 800 micrograms for systemic effects. The greater systemic effects of salmeterol are most likely to be due to greater potency relative to dose, although it may also have greater systemic bioavailability. The steeper dose response curve for heart rate with salmeterol indicates that it has a narrower therapeutic window than salbutamol and thus should be prescribed at the lowest effective dose.

PubMed Disclaimer

References

    1. Am Rev Respir Dis. 1972 Jun;105(6):883-90 - PubMed
    1. Br J Clin Pharmacol. 1992 Mar;33(3):342-5 - PubMed
    1. Mol Pharmacol. 1992 Oct;42(4):596-602 - PubMed
    1. BMJ. 1993 Feb 27;306(6877):543-5 - PubMed
    1. Thorax. 1993 Jun;48(6):656-8 - PubMed

Publication types

MeSH terms